Linda Barr, MD
Pulmonary Disease · Towson, MDNPI 1629033212
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,044 of the $8,088 with a category attached, or 87.1%. It is spread thinly across 47 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,583, 2.9 times the $896 reported in 2019.
Across 341 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Cook Incorporated$712
- AstraZeneca$595
- Cook Medical LLC$531
- Jazz Pharmaceuticals Inc.$500
- Takeda Pharmaceuticals U.S.A., Inc.$335
- plus $4K from 41 others
Across 17 payments — averaging $2080.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$27K
- Shire North American Group Inc$6K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Travel & lodging$1,03113%
- Food & beverage$7,04487%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Blue Rhino$1,219
- GIAPREZA$124
How this compares
$8,088 in reported general payments places this provider in the 75th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 264 | $289,463 |
| OfevNintedanib Esylate | 12 | $156,004 |
| Pirfenidone | 19 | $136,810 |
| Breo ElliptaFluticasone/Vilanterol | 110 | $68,579 |
| Spiriva RespimatTiotropium Bromide | 49 | $61,700 |
| NucalaMepolizumab | 13 | $47,955 |
| Dupixent SyringeDupilumab | 13 | $47,555 |
| Incruse ElliptaUmeclidinium Bromide | 42 | $38,248 |
| EliquisApixaban | 25 | $32,003 |
| Arnuity ElliptaFluticasone Furoate | 46 | $24,232 |
| BreynaBudesonide/Formoterol Fumarate | 33 | $10,089 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 208 | $9,621 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $9,117 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 19 | $7,434 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $7,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Arnuity Ellipta | $1,432 | $468,477475 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $211 | $217,70461 claims |
| PfizerEliquis | $50 | $32,00325 claims |
| AstraZenecaSymbicort | $595 | $9,11722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 297 pulmonary disease providers in Maryland.
Other pulmonary disease in Towson
- Mitchell SchwartzTowson$160K
- Brian BohnerTowson$75K
- Alan SchwartzBaltimore$1.3M
- Hitesh BatraBaltimore$611K
- Lonny YarmusBaltimore$582K
- Robert WiseBaltimore$389K
- da Wei LiaoBethesda$310K
- Ko Pen WangBaltimore$280K
- Hans LeeBaltimore$277K
- Angela ArgentoBaltimore$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.